InfuSystem Reports Record 2025 Revenue and Earnings Growth

InfuSystem Holdings ( (INFU) ) has shared an announcement.

As of the year ended December 31, 2025, InfuSystem reported its seventh consecutive year of record revenue, with net revenues rising to $143.4 million and 2025 adjusted EBITDA reaching $31.5 million, reflecting an 8% compound annual growth rate for both metrics. The business generated $24.4 million in cash flow from operations and maintained a conservative capital structure, with a net leverage ratio of 0.52x, a debt-to-equity ratio of 0.75x, and approximately $109 million in medical equipment assets.

The company highlighted its competitive advantages, including extensive payer coverage, a scalable revenue cycle management model in Patient Services, and a high-touch, ISO-certified biomedical services network in Device Solutions that creates barriers to entry. InfuSystem also underscored strategic growth from a series of partnerships and acquisitions between 2020 and 2024 in wound care, negative pressure wound therapy and biomedical services, which are intended to extend its oncology-based service capabilities into new therapies and reinforce its position as a high-value healthcare services platform.

The most recent analyst rating on (INFU) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on InfuSystem Holdings stock, see the INFU Stock Forecast page.

Spark’s Take on INFU Stock

According to Spark, TipRanks’ AI Analyst, INFU is a Neutral.

The score is driven primarily by improving financial performance (strong recent profitability, cash generation, and sharp deleveraging) and a supportive earnings outlook with margin/cost-savings visibility. These positives are partly offset by weak technical setup (price below key moving averages with negative momentum) and a relatively high P/E with no dividend support.

To see Spark’s full report on INFU stock, click here.

More about InfuSystem Holdings

InfuSystem Holdings, listed on the NYSE American under the ticker INFU, is a leading provider of medical equipment and patient services operating across the U.S. and Canada. Built on a long-standing oncology therapy model, the company now supports multiple therapies through a device-agnostic services platform, serving 19 of the top 20 U.S. hospital systems and participating in over 800 insurance networks covering more than 97% of the U.S. population.

The company manages a fleet of more than 100,000 devices, delivering solutions to hospitals, clinics, and home infusion providers via two primary segments: Patient Services and Device Solutions. Its offerings span oncology, pain management and wound care, biomedical services, consumables, inventory management, and equipment sales, rentals and leasing, supported by seven major service areas and more than 450 employees.

Average Trading Volume: 127,721

Technical Sentiment Signal: Hold

Current Market Cap: $174.9M

For an in-depth examination of INFU stock, go to TipRanks’ Overview page.